152 related articles for article (PubMed ID: 11820717)
1. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling.
Riisbro R; Christensen IJ; Høgdall C; Brünner N; Høgdall E
Int J Biol Markers; 2001; 16(4):233-9. PubMed ID: 11820717
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay.
Holten-Andersen MN; Schrohl AS; Brünner N; Nielsen HJ; Høgdall CK; Høgdall EV
Int J Biol Markers; 2003; 18(3):170-6. PubMed ID: 14535586
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor in blood transfusion components.
Riisbro R; Brünner N; Christensen IJ; Nielsen HJ
Transfus Med; 2004 Aug; 14(4):305-12. PubMed ID: 15285727
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
Fernebro E; Madsen RR; Fernö M; Brünner N; Bendahl P; Christensen IJ; Johnson A; Nilbert M
Eur J Cancer; 2001 Mar; 37(4):486-91. PubMed ID: 11267858
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
9. [Detection and clinical significance of plasma urokinase-type plasminogen activator and its soluble receptor in patients with multiple myeloma].
Luo LH; Xu GB; Lu XG
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Dec; 32(6):529-32. PubMed ID: 14712519
[TBL] [Abstract][Full Text] [Related]
10. Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
Jensen MK; Riisbro R; de Nully Brown P; Brünner N; Hasselbalch HC
Eur J Haematol; 2002 Jul; 69(1):43-9. PubMed ID: 12270061
[TBL] [Abstract][Full Text] [Related]
11. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.
Ostrowski SR; Ullum H; Goka BQ; Høyer-Hansen G; Obeng-Adjei G; Pedersen BK; Akanmori BD; Kurtzhals JA
J Infect Dis; 2005 Apr; 191(8):1331-41. PubMed ID: 15776381
[TBL] [Abstract][Full Text] [Related]
13. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
McCabe NP; Angwafo FF; Zaher A; Selman SH; Kouinche A; Jankun J
Oncol Rep; 2000; 7(4):879-82. PubMed ID: 10854562
[TBL] [Abstract][Full Text] [Related]
14. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
15. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
16. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
Riisbro R; Christensen IJ; Nielsen HJ; Brünner N; Nilbert M; Fernebro E
Int J Biol Markers; 2005; 20(2):93-102. PubMed ID: 16011039
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of soluble urokinase plasminogen activator receptor, soluble ST2, and IL-33 in bronchopulmonary dysplasia.
Tunc T; Cekmez F; Yildirim S; Bulut O; Ince Z; Saldir M; Aydemir G; Yaman H; Coban A
Pediatr Res; 2014 Jun; 75(6):788-92. PubMed ID: 24603291
[TBL] [Abstract][Full Text] [Related]
18. Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals.
Chew-Harris J; Appleby S; Richards AM; Troughton RW; Pemberton CJ
Clin Biochem; 2019 Jul; 69():36-44. PubMed ID: 31129182
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC).
Begum FD; Høgdall EV; Riisbro R; Christensen IJ; Engelholm SA; Jørgensen M; Pedersen BN; Høgdall CK
APMIS; 2006 Oct; 114(10):675-81. PubMed ID: 17004970
[TBL] [Abstract][Full Text] [Related]
20. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
